Compare Kohl's Corporation (KSS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs GeneDx Holdings Corp — how do they compare? Kohl's Corporation trades at $19.01 (market cap $2.06B), while GeneDx Holdings Corp trades at $62.68 (market cap $1.83B). The key difference: Kohl's Corporation and GeneDx Holdings Corp are close in size by market cap, and Kohl's Corporation pays a 2.76% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| KSS | WGS | |
|---|---|---|
Market Cap | $2.06B | $1.83B |
Sector | Consumer Cyclical | Technology |
52-Week High | $24.71 | $167.51 |
52-Week Low | $10.73 | $34.51 |
Enterprise Value | $8.16B | $1.83B |
Dividend Yield | 2.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $18.12, up 4.74% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $16.75. The stock shows low valuation multiples with a P/E of 7.38 and P/S of 0.13, while recent earnings have beaten expectations. Revenue has declined from $19.4B in 2022 to $16.2B in 2025, but net income improved to $109M. The company is focusing on proprietary brands and operational improvements under new leadership.
The outlook suggests a turnaround opportunity with attractive valuations and recent operational progress, but risks include persistent revenue declines and competitive pressures. Investor sentiment is mixed, with analysts divided between buy and hold ratings. Upside depends on successful execution of the company's revitalization strategy amid a challenging retail environment.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
